1. Home
  2. DNLI vs TNDM Comparison

DNLI vs TNDM Comparison

Compare DNLI & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • TNDM
  • Stock Information
  • Founded
  • DNLI 2013
  • TNDM 2006
  • Country
  • DNLI United States
  • TNDM United States
  • Employees
  • DNLI N/A
  • TNDM N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • TNDM Medical/Dental Instruments
  • Sector
  • DNLI Health Care
  • TNDM Health Care
  • Exchange
  • DNLI Nasdaq
  • TNDM Nasdaq
  • Market Cap
  • DNLI 2.1B
  • TNDM N/A
  • IPO Year
  • DNLI 2017
  • TNDM 2013
  • Fundamental
  • Price
  • DNLI $13.60
  • TNDM $19.16
  • Analyst Decision
  • DNLI Strong Buy
  • TNDM Buy
  • Analyst Count
  • DNLI 16
  • TNDM 15
  • Target Price
  • DNLI $37.57
  • TNDM $46.07
  • AVG Volume (30 Days)
  • DNLI 1.3M
  • TNDM 1.8M
  • Earning Date
  • DNLI 05-06-2025
  • TNDM 05-01-2025
  • Dividend Yield
  • DNLI N/A
  • TNDM N/A
  • EPS Growth
  • DNLI N/A
  • TNDM N/A
  • EPS
  • DNLI N/A
  • TNDM N/A
  • Revenue
  • DNLI N/A
  • TNDM $940,203,000.00
  • Revenue This Year
  • DNLI N/A
  • TNDM $8.70
  • Revenue Next Year
  • DNLI $497.02
  • TNDM $11.06
  • P/E Ratio
  • DNLI N/A
  • TNDM N/A
  • Revenue Growth
  • DNLI N/A
  • TNDM 25.74
  • 52 Week Low
  • DNLI $13.30
  • TNDM $17.64
  • 52 Week High
  • DNLI $33.33
  • TNDM $53.69
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 34.19
  • TNDM 31.64
  • Support Level
  • DNLI $13.67
  • TNDM $19.12
  • Resistance Level
  • DNLI $14.84
  • TNDM $21.15
  • Average True Range (ATR)
  • DNLI 0.77
  • TNDM 0.93
  • MACD
  • DNLI 0.12
  • TNDM 0.52
  • Stochastic Oscillator
  • DNLI 9.90
  • TNDM 38.77

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Share on Social Networks: